Should I buy or sell Cue Biopharma stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cue Biopharma in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CUE shares. View CUE analyst ratings or view top-rated stocks .

What is Cue Biopharma's stock price target for 2024?

4 Wall Street analysts have issued 1-year target prices for Cue Biopharma's shares. Their CUE share price targets range from $6.00 to $10.00. On average, they anticipate the company's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 406.3% from the stock's current price. View analysts price targets for CUE or view top-rated stocks among Wall Street analysts .

How have CUE shares performed in 2024?

Cue Biopharma's stock was trading at $2.64 at the beginning of 2024. Since then, CUE stock has decreased by 40.2% and is now trading at $1.58. View the best growth stocks for 2024 here .

When is Cue Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our CUE earnings forecast .

How were Cue Biopharma's earnings last quarter?

Cue Biopharma, Inc. (NASDAQ:CUE) issued its earnings results on Tuesday, May, 9th. The company reported ($0.29) earnings per share for the quarter, beating analysts' consensus estimates of ($0.33) by $0.04. The business earned $0.19 million during the quarter, compared to the consensus estimate of $0.30 million. Cue Biopharma had a negative trailing twelve-month return on equity of 112.26% and a negative net margin of 924.10%.

What other stocks do shareholders of Cue Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cue Biopharma investors own include Provention Bio (PRVB) , NVIDIA (NVDA) , OPKO Health (OPK) , Dynavax Technologies (DVAX) , VBI Vaccines (VBIV) , AbbVie (ABBV) , Gilead Sciences (GILD) , Pfizer (PFE) , AT&T (T) and Advanced Micro Devices (AMD) .

Who are Cue Biopharma's major shareholders?

Cue Biopharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include Wedmont Private Capital (0.08%). Insiders that own company stock include Aaron GL Fletcher, Anish Suri , Daniel R Passeri , Kerri-Ann Millar and Peter A Kiener. View institutional ownership trends .

How do I buy shares of Cue Biopharma?

Shares of CUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CUE

Cue Biopharma (CUE) Stock Price, News & Analysis

→ The Hard Truth About Investing For Retirement (From Insiders Exposed) (Ad)

Free CUE Stock Alerts

$1.54

-0.04 (-2.22%)

(As of 12:44 PM ET)

Compare

Today's Range: $1.52
▼
$1.61
50-Day Range: $1.50
▼
$2.55
52-Week Range: $1.47
▼
$5.12

Volume: 72,979 shs
Average Volume: 266,854 shs
Market Capitalization: $75.15 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.00

Get Cue Biopharma alerts:

Cue Biopharma MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 406.3% Upside
$8.00 Price Target
Short Interest: Bearish
8.63% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.58
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.00) to ($0.94) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.29 out of 5 stars

Medical Sector

308th out of 918 stocks

Pharmaceutical Preparations Industry

130th out of 426 stocks

3.5

Analyst's Opinion

Consensus Rating
Cue Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Cue Biopharma has only been the subject of 4 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
8.63% of the outstanding shares of Cue Biopharma have been sold short.
Short Interest Ratio / Days to Cover
Cue Biopharma has a short interest ratio ("days to cover") of 15.8, which indicates bearish sentiment.
Change versus previous month
Short interest in Cue Biopharma has recently increased by 1.94%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Cue Biopharma does not currently pay a dividend.
Dividend Growth
Cue Biopharma does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Cue Biopharma has received a 74.25% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Preclinical research services for physical health", "Basic medical research services", and "Clinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Cue Biopharma is -0.58.

2.2

News and Social Media Coverage

News Sentiment
Cue Biopharma has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.
Search Interest
Only 3 people have searched for CUE on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
Only 4 people have added Cue Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cue Biopharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
10.24% of the stock of Cue Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 35.04% of the stock of Cue Biopharma is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Cue Biopharma are expected to grow in the coming year, from ($1.00) to ($0.94) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cue Biopharma is -1.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cue Biopharma is -1.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Cue Biopharma has a P/B Ratio of 1.93. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Here’s how to start a “Weekend Side Hustle” from your sofa

Here’s how you can start your very own “Weekend Side Hustle” right from the comfort of your sofa! It doesn't matter if you have a multi-million dollar retirement account… Or if you’re just starting out with a few thousand.

Weekend after weekend!

About Cue Biopharma Stock (NASDAQ:CUE)

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

CUE Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CUE Stock News Headlines

April 10, 2024 | americanbankingnews.com

Cue Biopharma (NASDAQ:CUE) Given "Buy" Rating at Stifel Nicolaus

April 10, 2024 | americanbankingnews.com

Cue Biopharma (NASDAQ:CUE) Receives "Outperform" Rating from Oppenheimer

April 19, 2024 | The Bull Report (Ad)

Healthcare Takes A Big Step Forward With The Help Of AI

The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.

April 9, 2024 | markets.businessinsider.com

Forecasting The Future: 4 Analyst Projections For Cue Biopharma

April 9, 2024 | finanznachrichten.de

Cue Biopharma, Inc.: Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights

April 9, 2024 | finance.yahoo.com

Cue Biopharma Inc (CUE) Q4 2023 Earnings Call Transcript Highlights: Strategic Alliances and ...

April 8, 2024 | markets.businessinsider.com

Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights

April 8, 2024 | globenewswire.com

Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights

April 19, 2024 | The Bull Report (Ad)

Healthcare Takes A Big Step Forward With The Help Of AI

The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.

April 8, 2024 | msn.com

Options Volatility and Implied Earnings Moves Today, April 08, 2024

April 7, 2024 | markets.businessinsider.com

Cue Biopharma is about to announce earnings — here's what Wall Street expects

April 2, 2024 | investorplace.com

CUE Stock Earnings: Cue Biopharma Misses EPS, Beats Revenue for Q4 2023

April 2, 2024 | finance.yahoo.com

Cue Biopharma to Host Business Update Call and Webcast

April 2, 2024 | finance.yahoo.com

Cue Biopharma to Host Business Update Call and Webcast

April 1, 2024 | msn.com

Carisma to cut 37% of workforce, stock falls 8%

March 13, 2024 | markets.businessinsider.com

What 4 Analyst Ratings Have To Say About Silence Therapeutics

February 29, 2024 | finance.yahoo.com

Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium

February 29, 2024 | globenewswire.com

Cue Biopharma's Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium

February 27, 2024 | morningstar.com

Cue Biopharma Inc Ordinary Shares

February 26, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Cardinal Health (CAH), Intellia Therapeutics (NTLA) and Cue Biopharma (CUE)

February 6, 2024 | finance.yahoo.com

Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

February 6, 2024 | finance.yahoo.com

Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

January 17, 2024 | finance.yahoo.com

Cue Biopharma (NASDAQ:CUE) investors are sitting on a loss of 80% if they invested three years ago

December 14, 2023 | investorplace.com

CUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q3 2023

December 7, 2023 | finance.yahoo.com

Are Medical Stocks Lagging Corvus Pharmaceuticals (CRVS) This Year?

November 22, 2023 | finance.yahoo.com

Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit

November 12, 2023 | finance.yahoo.com

Cue Biopharma, Inc. (NASDAQ:CUE) Q3 2023 Earnings Call Transcript

See More Headlines

Receive CUE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cue Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 5/09/2023
Today: 4/19/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:CUE
CUSIP: N/A
CIK: 1645460
Web: www.cuebiopharma.com
Phone: (617) 949-2680
Fax: N/A
Employees: 53
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $8.00
High Stock Price Target: $10.00
Low Stock Price Target: $6.00
Potential Upside/Downside: +406.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.10)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-50,730,000.00
Net Margins: -924.10%
Pretax Margin: -924.10%
Return on Equity: -112.26%
Return on Assets: -71.14%

Debt

Debt-to-Equity Ratio: 0.11
Current Ratio: 3.01
Quick Ratio: 3.01

Sales & Book Value

Annual Sales: $5.49 million
Price / Sales: 14.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.82 per share
Price / Book: 1.93

Miscellaneous

Outstanding Shares: 48,640,000
Free Float: 43,662,000
Market Cap: $76.85 million
Optionable: Optionable
Beta: 2.02

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Mr. Daniel R. Passeri J.D. (Age 63)
M.Sc., CEO & Director
Comp: $985.72k
Dr. Anish Suri Ph.D. (Age 50)
President & Chief Scientific Officer
Comp: $641.98k
Ms. Kerri-Ann Millar (Age 54)
Chief Financial Officer
Comp: $559.03k
Dr. Ronald D. Seidel III (Age 48)
Ph.D., Co-Founder
Comp: $316.63k
Dr. Rodolfo J. Chaparro (Age 51)
Co-Founder & Senior Advisor
Comp: $316.63k
Dr. Steven C. Almo (Age 63)
Co-Founder and Chairman of Scientific & Clinical Advisory Board
George B. Zavoico Ph.D.
VP of Investor Relations & Corporate Development
Mr. Colin G. Sandercock J.D. (Age 67)
MSE, Senior VP, General Counsel & Secretary
Comp: $381.42k
Dr. Matteo Levisetti M.D. (Age 55)
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CUE Stock Analysis - Frequently Asked Questions

Should I buy or sell Cue Biopharma stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cue Biopharma in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CUE shares.
View CUE analyst ratings or view top-rated stocks.
What is Cue Biopharma's stock price target for 2024?: 4 Wall Street analysts have issued 1-year target prices for Cue Biopharma's shares. Their CUE share price targets range from $6.00 to $10.00. On average, they anticipate the company's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 406.3% from the stock's current price.
View analysts price targets for CUE or view top-rated stocks among Wall Street analysts.
How have CUE shares performed in 2024?: Cue Biopharma's stock was trading at $2.64 at the beginning of 2024. Since then, CUE stock has decreased by 40.2% and is now trading at $1.58.
View the best growth stocks for 2024 here.
When is Cue Biopharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our CUE earnings forecast.

How were Cue Biopharma's earnings last quarter?: Cue Biopharma, Inc. (NASDAQ:CUE) issued its earnings results on Tuesday, May, 9th. The company reported ($0.29) earnings per share for the quarter, beating analysts' consensus estimates of ($0.33) by $0.04. The business earned $0.19 million during the quarter, compared to the consensus estimate of $0.30 million. Cue Biopharma had a negative trailing twelve-month return on equity of 112.26% and a negative net margin of 924.10%.
What other stocks do shareholders of Cue Biopharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Cue Biopharma investors own include Provention Bio (PRVB), NVIDIA (NVDA), OPKO Health (OPK), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), AbbVie (ABBV), Gilead Sciences (GILD), Pfizer (PFE), AT&T (T) and Advanced Micro Devices (AMD).
Who are Cue Biopharma's major shareholders?: Cue Biopharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include Wedmont Private Capital (0.08%). Insiders that own company stock include Aaron GL Fletcher, Anish Suri, Daniel R Passeri, Kerri-Ann Millar and Peter A Kiener.
View institutional ownership trends.
How do I buy shares of Cue Biopharma?: Shares of CUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CUE) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial